Blockade of @entity630 chemokine receptors ameliorates @entity358 in XXXX .

@entity12426 @entity13945 @entity738 @entity14013 @entity19 @entity5 @entity22425 @entity39 @entity42711 @entity5478 @entity1961 @entity358 @entity2883 @entity370 @entity630 @entity15369
@entity370 is a @entity738 of unknown aetiology. We identified immunological targets for the treatment of @entity358 using a @entity19 model generated with @entity5478 . Sensitisation and challenge using heat-killed @entity5478 and dendritic cells (DCs) were performed to produce @entity358 in C57BL/6 @entity19 . Immunological analyses using ELISA as well as cDNA microarray analysis were used to search for cytokines or chemokines associated with the formation of @entity738 in the lungs. Co-administration of @entity5478 and DCs reproducibly induced the formation of @entity358 , which resembled @entity738 . The cDNA microarray assay demonstrated that the gene expression of @entity12426 and @entity15369 , ligands for @entity14013 , and of @entity22425 , a ligand for @entity13945 , was strongly upregulated during @entity2883 . ELISA confirmed that levels of @entity12426 and @entity15369 as well as T-helper (Th)1 cytokines and chemokines including @entity5 @entity39 factor-a and interferon-y were elevated in bronchoalveolar lavage fluid (BALF). The blockade of @entity630 chemokine receptors using @entity42711 , a dual blocker for @entity14013 and @entity13945 , led to reduced numbers of @entity14013 + @entity1961 + and @entity13945 + @entity1961 + T-cells in BALF. Furthermore, administration of @entity42711 ameliorated the @entity2883 . The targeted inhibition of @entity630 chemokines might be useful for inhibiting @entity630 -biased @entity738 , including @entity370 .
